Vivus Obesity Pill Scores With Phase III Data, But Still Faces Market Hurdles

With complete Phase III results for its obesity drug Qnexa in hand, Vivus has aced one important test on the road to commercialization. But other major hurdles remain - including passing regulatory muster and convincing a partner to sign up to back a drug that combines generic pills